NYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free GKOS Stock Alerts $85.45 -0.04 (-0.05%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$85.04▼$87.0850-Day Range$84.31▼$96.4252-Week Range$45.38▼$97.24Volume343,297 shsAverage Volume739,930 shsMarket Capitalization$4.23 billionP/E RatioN/ADividend YieldN/APrice Target$91.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Glaukos alerts: Email Address Glaukos MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside7.4% Upside$91.80 Price TargetShort InterestBearish7.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.89Based on 12 Articles This WeekInsider TradingSelling Shares$31.07 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.12) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 starsMedical Sector315th out of 947 stocksSurgical & Medical Instruments Industry37th out of 99 stocks 2.4 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $91.80, Glaukos has a forecasted upside of 7.4% from its current price of $85.45.Amount of Analyst CoverageGlaukos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.46% of the outstanding shares of Glaukos have been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Glaukos has recently increased by 1.65%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlaukos has received a 65.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical laser systems", "Medical technology engineering", and "Surgical instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Glaukos is -0.90. Previous Next 3.3 News and Social Media Coverage News SentimentGlaukos has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Glaukos this week, compared to 4 articles on an average week.MarketBeat Follows6 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,068,090.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.12) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -30.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -30.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 9.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMy next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About Glaukos Stock (NYSE:GKOS)Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.Read More GKOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GKOS Stock News HeadlinesMarch 11, 2024 | insidertrades.comInsider Selling: Glaukos Co. (NYSE:GKOS) Director Sells 5,000 Shares of StockMarch 18, 2024 | finance.yahoo.comGKOS Apr 2024 140.000 callMarch 19, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 18, 2024 | americanbankingnews.comEquities Analysts Issue Forecasts for Glaukos Co.'s Q1 2024 Earnings (NYSE:GKOS)March 16, 2024 | finance.yahoo.comGKOS Apr 2024 92.500 putMarch 16, 2024 | ca.finance.yahoo.comGKOS Apr 2024 80.000 putMarch 16, 2024 | americanbankingnews.comBrokers Set Expectations for Glaukos Co.'s FY2026 Earnings (NYSE:GKOS)March 10, 2024 | americanbankingnews.comGilbert H. Kliman Sells 5,000 Shares of Glaukos Co. (NYSE:GKOS) StockMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 27, 2024 | finance.yahoo.comGlaukos Corp Director Mark Foley Sells 4,560 SharesFebruary 26, 2024 | markets.businessinsider.comGlaukos Corporation: Hold Rating with Cautious Optimism Amidst iDose Launch and Reimbursement UncertaintiesFebruary 24, 2024 | msn.comGlaukos (GKOS) Price Target Increased by 13.83% to 104.69February 23, 2024 | finance.yahoo.comGlaukos Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 22, 2024 | benzinga.comGlaukos Stock (NYSE:GKOS), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comGKOS Apr 2024 47.500 putFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS) and Glaukos (GKOS)February 22, 2024 | msn.comGlaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/YFebruary 22, 2024 | finance.yahoo.comGlaukos Corporation (NYSE:GKOS) Q4 2023 Earnings Call TranscriptFebruary 21, 2024 | finance.yahoo.comGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comGlaukos Corp (GKOS) Reports Increased Sales but Widening Losses in Q4 and Full Year 2023February 21, 2024 | finance.yahoo.comGlaukos (GKOS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 21, 2024 | businesswire.comGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comIs Glaukos Corporation (NYSE:GKOS) Trading At A 41% Discount?February 20, 2024 | markets.businessinsider.comGlaukos is about to announce its earnings — here's what Wall Street expectsFebruary 20, 2024 | msn.comGlaukos Q4 2023 Earnings PreviewFebruary 17, 2024 | finance.yahoo.comGKOS Mar 2024 82.500 putFebruary 17, 2024 | finance.yahoo.comGKOS Apr 2024 130.000 callSee More Headlines Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/18/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:GKOS CUSIPN/A CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees783Year FoundedN/APrice Target and Rating Average Stock Price Target$91.80 High Stock Price Target$108.00 Low Stock Price Target$65.00 Potential Upside/Downside+7.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-42.79% Pretax Margin-42.49% Return on Equity-22.67% Return on Assets-11.50% Debt Debt-to-Equity Ratio0.77 Current Ratio5.34 Quick Ratio4.78 Sales & Book Value Annual Sales$314.71 million Price / Sales13.43 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book9.03Miscellaneous Outstanding Shares49,470,000Free Float45,611,000Market Cap$4.23 billion OptionableOptionable Beta1.08 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Thomas William Burns (Age 63)Chairman & CEO Comp: $1.5MMr. Joseph E. Gilliam (Age 48)President & COO Comp: $974.59kMr. Alex R. Thurman (Age 54)Senior VP & CFO Comp: $373.4kMr. Chris M. Calcaterra (Age 64)Executive Vice President of Global Commercial Operations Comp: $198.66kDr. Tomas Navratil Ph.D. (Age 47)Chief Development Officer Comp: $721.51kDr. Mory Gharib Ph.D.Co-FounderMr. Christopher William LewisVice President of Investor Relations & Corporate AffairsMs. Diana A. SchererVP of Compliance & Deputy General CounselMs. Michele M. AllegrettoSenior Vice President of Human ResourcesMs. Jane E. Rady (Age 76)Senior Vice President of Corporate Strategy & Business Development More ExecutivesKey CompetitorsMerit Medical SystemsNASDAQ:MMSIHaemoneticsNYSE:HAEAxonicsNASDAQ:AXNXiRhythm TechnologiesNASDAQ:IRTCInspire Medical SystemsNYSE:INSPView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 3,279 shares on 3/11/2024Ownership: 10.586%Gilbert H KlimanSold 5,000 sharesTotal: $441,250.00 ($88.25/share)Wellington Management Group LLPSold 715,921 shares on 3/5/2024Ownership: 2.710%Fisher Asset Management LLCBought 2,718 shares on 3/5/2024Ownership: 0.005%Goldman Sachs Group Inc.Bought 18,639 shares on 3/1/2024Ownership: 0.256%View All Insider TransactionsView All Institutional Transactions GKOS Stock Analysis - Frequently Asked Questions Should I buy or sell Glaukos stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GKOS shares. View GKOS analyst ratings or view top-rated stocks. What is Glaukos' stock price target for 2024? 8 brokerages have issued twelve-month price objectives for Glaukos' shares. Their GKOS share price targets range from $65.00 to $108.00. On average, they predict the company's share price to reach $91.80 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price. View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts. How have GKOS shares performed in 2024? Glaukos' stock was trading at $79.49 at the start of the year. Since then, GKOS stock has increased by 7.5% and is now trading at $85.45. View the best growth stocks for 2024 here. Are investors shorting Glaukos? Glaukos saw a decline in short interest in the month of February. As of February 15th, there was short interest totaling 3,630,000 shares, a decline of 8.6% from the January 31st total of 3,970,000 shares. Based on an average trading volume of 829,900 shares, the days-to-cover ratio is presently 4.4 days. View Glaukos' Short Interest. When is Glaukos' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GKOS earnings forecast. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) announced its earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The medical instruments supplier had revenue of $82.40 million for the quarter, compared to analyst estimates of $81 million. Glaukos had a negative net margin of 42.79% and a negative trailing twelve-month return on equity of 22.67%. The business's revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.53) EPS. What ETFs hold Glaukos' stock? ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Fidelity Disruptive Medicine ETF (FMED), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Xtrackers S&P SmallCap 600 ESG ETF (SMLE). What guidance has Glaukos issued on next quarter's earnings? Glaukos updated its FY 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million. What is Thomas W. Burns' approval rating as Glaukos' CEO? 10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA). When did Glaukos IPO? (GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.73%), Vanguard Group Inc. (10.59%), Brown Capital Management LLC (5.53%), Wellington Management Group LLP (2.71%), Artisan Partners Limited Partnership (2.51%) and Dimensional Fund Advisors LP (1.89%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GKOS) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.